Drugs / Erdafitinib
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed urothelial carcinoma 3 milestones | |||||
| Filed | EU (EMA) | — | urothelial carcinoma | 2023-09-08 | “announced today the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of erdafitinib” jnj.com ↗ “marketing authorisationsubmittedto the EMA in September 2023” jnj.com ↗ |
| Filed | US (FDA) | BALVERSA® | urothelial carcinoma | 2023-08-29 | “On August 29, Janssen submitted a supplemental New Drug Application (sNDA) to the U.S. FDA seeking full approval of erdafitinib in this indication” jnj.com ↗ |
| Filed | US (FDA) | — | urothelial carcinoma | 2018-09-18 | “A New Drug Application was submitted to the FDA for esketamine nasal spray, a rapidly acting antidepressant for treatment-resistant depression in adults and erdafitinib” jnj.com ↗ “Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Erdafitinib for the Treatment of Metastatic Urothelial Cancer” jnj.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Approved | EU (EMA) | Balversa | — | 2024-08-22 | europa.eu ↗ |
| Label expansion | US (FDA) | BALVERSA | — | 2024-01-19 | fda.gov ↗ |
| Approved | US (FDA) | BALVERSA | — | 2019-04-12 | fda.gov ↗ |
Trials 40
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06204614 | Jun 2024 → Jul 2028 expected | infiltrating bladder urothelial carcinoma | Brigham and Women's Hospital | Enrolling by invitation | No outcome recorded |
| Phase 114 trials · 1 met primary | ||||||
| Phase 1 | NCT05567185 | Mar 2023 → Mar 2025 overdue | urinary bladder cancer | Janssen Pharmaceutical K.K. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04963153 | Jul 2022 → Dec 2026 expected | ureter cancer, urethra cancer, urothelial carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04330248 | Mar 2020 → Jun 2022 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT03587363 | Dec 2018 → Dec 2020 | — | Janssen Research & Development, LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03547037 | Aug 2018 → Jul 2022 | neoplasm | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT03238196 | Aug 2017 → Apr 2021 | breast cancer | Vanderbilt-Ingram Cancer Center | Completed | Met primary |
| Phase 1 | NCT03135106 | Apr → Sep 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03066687 | Mar → May 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02692677 | Mar → Aug 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02466815 | Jun → Aug 2015 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02218073 | Oct → Dec 2014 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02231489 | Sep → Nov 2014 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01962532 | Aug 2013 → Jan 2016 | gastroesophageal junction adenocarcinoma, lymphoma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01703481 | Jun 2012 → Jul 2017 | lymphoma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05316155 | Apr 2022 → Mar 2028 expected | non-invasive bladder urothelial carcinoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03732703 | Apr 2019 → Dec 2024 | refractory plasma cell neoplasm | Multiple Myeloma Research Consortium | Completed | No outcome recorded |
| Phase 1/2 | NCT03473743 | Apr 2018 → Sep 2022 overdue | urothelial carcinoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02421185 | May 2015 → May 2019 | hepatocellular carcinoma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 217 trials · 1 met primary | ||||||
| Phase 2 | NCT05859334 | Jan 2024 → Oct 2026 expected | grade II glioma, grade III glioma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT05564416 | Oct 2023 → Jan 2024 | infiltrating bladder urothelial carcinoma, renal pelvis/ureter urothelial carcinoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 2 | NCT06511648 | Mar 2023 → Jul 2026 overdue | infiltrating bladder urothelial carcinoma | Spanish Oncology Genito-Urinary Group | Recruiting | No outcome recorded |
| Phase 2 | NCT04917809 | Feb 2022 → Aug 2027 expected | urinary bladder cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04754425 | Jul 2021 → Feb 2026 | castration-resistant prostate carcinoma, metastatic carcinoma in the bone, prostate adenocarcinoma, prostate small cell carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT03999515 | Apr 2020 → Jun 2021 | castration-resistant prostate carcinoma, metastatic prostate carcinoma, prostate adenocarcinoma | University of Washington | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04172675 | Feb 2020 → Jul 2024 | urinary bladder neoplasm | Janssen Research & Development, LLC | Completed | Met primary |
| Phase 2 | NCT04083976 | Nov 2019 → Dec 2023 | neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT06308822 | Aug 2018 → Jul 2022 overdue | adult lymphoma, plasma cell myeloma, refractory malignant neoplasm | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06351371 | Jul 2018 → Jun 2022 overdue | cancer | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03210714 | Jun 2018 → Sep 2023 overdue | Ewing sarcoma/peripheral primitive neuroectodermal tumor, Langerhans cell histiocytosis, Wilms tumor, childhood ependymoma +9 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03155620 | Jul 2017 → Mar 2025 overdue | Ewing sarcoma, Langerhans cell histiocytosis, Wilms tumor, conventional osteosarcoma +13 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02952573 | Jun 2017 → Nov 2018 | plasma cell myeloma | University Health Network, Toronto | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02925234 | Aug 2016 → Sep 2027 expected | cancer | The Netherlands Cancer Institute | Recruiting | Mixed |
| Phase 2 | NCT02699606 | Jul 2016 → Oct 2021 | neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02465060 | Aug 2015 → Dec 2027 expected | breast carcinoma, carcinoma of esophagus, cervical carcinoma, colon carcinoma +17 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02365597 | Apr 2015 → Sep 2022 overdue | urothelial carcinoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06319820 | Apr 2024 → Jun 2028 expected | urinary bladder carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT03390504 | Mar 2018 → Apr 2024 overdue | urothelial carcinoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06328491 | May → Aug 2022 | malignant sex cord stromal tumor of ovary | University Health Network, Toronto | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03825484 | — | — | Janssen Scientific Affairs, LLC | Approved for marketing | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03827850 Comparator | Mar 2019 → Sep 2022 | non-small cell lung carcinoma, squamous cell lung carcinoma | Lung Cancer Group Cologne | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 27
| Date | Issuer | Release |
|---|---|---|
| 2026-03-13 | Janssen Research & Development, LLC | Results Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate‑risk non–muscle-invasive bladder cancer jnj.com ↗
The study met its primary safety endpoint and demonstrated complete and durable responses in patients with recurrent intermediate-risk disease, along with encouraging recurrence-free outcomes in high-risk disease. |
| 2026-03-13 | Janssen Research & Development, LLC | Results Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer jnj.com ↗ |
| 2024-08-23 | Janssen Research & Development, LLC | Regulatory European Commission approves BALVERSA®▼ (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma jnj.com ↗
Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved BALVERSA®▼(erdafitinib) as a once-daily oral monotherapy for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (mUC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. |
| 2024-08-23 | Janssen Research & Development, LLC | Regulatory European Commission approves BALVERSA®▼ (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma jnj.com ↗
European Commission approves BALVERSA®▼ (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma |
| 2024-06-28 | Janssen Research & Development, LLC | Regulatory CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients jnj.com ↗
Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorisation for BALVERSA®(erdafitinib) as a once-daily oral monotherapy for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. |
| 2024-06-28 | Janssen Research & Development, LLC | Regulatory CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations jnj.com ↗
CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations |
| 2024-01-19 | Janssen Research & Development, LLC | Regulatory U.S. Food and Drug Administration Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations jnj.com ↗
This FDA action converts the April 2019accelerated approvalof BALVERSA® to a full approval based on the clinical and overall survival benefit observed in the Phase 3 THOR study. |
| 2024-01-19 | Janssen Research & Development, LLC | Regulatory U.S. Food and Drug Administration Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations jnj.com ↗
U.S. Food and Drug Administration Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations |
| 2023-10-22 | Janssen Research & Development, LLC | Results First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations jnj.com ↗
In C3, 87 percent of the 27 patients having at least one response assessment with IR NMIBC achieved a complete response (CR). |
| 2023-10-22 | Janssen Research & Development, LLC | Results First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations jnj.com ↗
Phase 1 results show a manageable safety profile with limited systemic toxicity, and early complete responses in patients with high-risk and intermediate-risk NMIBC |
| 2023-10-21 | Janssen Research & Development, LLC | Results Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with BALVERSA® (erdafitinib) Versus Chemotherapy jnj.com ↗
The six-month RFS in patients randomized to BALVERSA®was 96 percent compared to 73 percent in those assigned to chemotherapy. |
| 2023-10-21 | Janssen Research & Development, LLC | Results Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor jnj.com ↗
Data from Cohort 1 of the Phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy |
| 2023-09-08 | Janssen Research & Development, LLC | Regulatory Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Erdafitinib for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer with Susceptible FGFR Alterations jnj.com ↗
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of erdafitinib |
| 2023-09-08 | Janssen Research & Development, LLC | Regulatory Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Erdafitinib for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer with Susceptible FGFR Alterations jnj.com ↗
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Erdafitinib for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer with Susceptible FGFR Alterations |
| 2023-08-29 | Janssen Research & Development, LLC | Regulatory Janssen Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of BALVERSA® (erdafitinib) for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations jnj.com ↗
Janssen Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of BALVERSA® (erdafitinib) for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations |
| 2023-08-28 | Janssen Research & Development, LLC | Regulatory Janssen Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of BALVERSA® (erdafitinib) for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations jnj.com ↗
The sNDA submission for BALVERSA®is intended to satisfy the regulatory requirements to confirm the clinical benefit of BALVERSA®based on the randomized data from Cohort 1 of the Phase 3 THOR study. |
| 2023-06-05 | Janssen Research & Development, LLC | Results Janssen Announces BALVERSA® (erdafitinib) Improved Overall Survival Versus Chemotherapy in Patients with Metastatic or Unresectable Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations After Prior Anti-PD-(L)1 Treatment jnj.com ↗
In this cohort, the study met its primary endpoint of overall survival (OS) and reduced the risk of death by 36 percent. |
| 2023-06-05 | Janssen Research & Development, LLC | Results Janssen Announces BALVERSA® (erdafitinib) Improved Overall Survival Versus Chemotherapy in Patients with Metastatic or Unresectable Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations After Prior AntiPD-(L)1 Treatmen jnj.com ↗
In this cohort, the study met its primary endpoint of overall survival (OS) and reduced the risk of death by 36 percent. |
| 2022-06-07 | Janssen Research & Development, LLC | Results Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations jnj.com ↗
At a planned interim analysis (IA), responseswere observed across a variety of FGFR-driven solid tumors for patients who had exhausted standard treatment options prior to being treated with BALVERSA®. |
| 2022-06-07 | Janssen Research & Development, LLC | Results Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations jnj.com ↗
At a planned interim analysis (IA), responses were observed across a variety of FGFR-driven solid tumors for patients who had exhausted standard treatment options prior to being treated with BALVERSA®. |
| 2021-09-17 | Janssen Research & Development, LLC | Results Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor jnj.com ↗
Preliminary findings suggest robust clinical activity and depth of response in patients treated with BALVERSA®in combination with cetrelimab. |
| 2021-09-17 | Janssen Research & Development, LLC | Results Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor jnj.com ↗
Preliminary findings suggest robust clinical activity and depth of response in patients treated with BALVERSA® in combination with cetrelimab. |
| 2019-04-15 | Janssen Research & Development, LLC | Regulatory BALVERSA™ (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations jnj.com ↗
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that BALVERSA™ (erdafitinib) received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC) which has susceptible fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations and who have progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. |
| 2019-04-12 | Janssen Research & Development, LLC | Regulatory BALVERSA™ (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations jnj.com ↗
BALVERSA™ (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations |
| 2018-09-18 | Janssen Research & Development, LLC | Regulatory Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Erdafitinib for the Treatment of Metastatic Urothelial Cancer jnj.com ↗
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of erdafitinib for the treatment of patients with locally advanced or metastatic urothelial cancer (UC) and certain fibroblast growth factor receptor (FGFR) genetic alterations whose tumors have progressed after prior chemotherapy. |
| 2018-06-03 | Janssen Research & Development, LLC | Results Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer jnj.com ↗
Treatment with investigational compound erdafitinib demonstrated durable responses in patients with metastatic urothelial cancer with genetic alterations |
| 2018-03-15 | Janssen Research & Development, LLC | Regulatory Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer jnj.com ↗
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for erdafitinib in the treatment of urothelial cancer. |
All press releases naming this drug 31 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 45 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | erdafitinib | “This phase 1, open-label, multicenter, single-arm, dose-escalation study aimed to evaluate safety, pharmacokinetics (PK), and pharmacodynamics of erdafitinib (JNJ-42756493), an...” PMID 28965185 ↗ Sep 201735“A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants...” NCT06319820 ↗ “Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.” PMID 31088831 ↗ May 2019 “JNJ-42756493 (erdafitinib)” NCT02421185 ↗ |
| Known as | Balversa | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545376 ↗ |
| Known as | ERDA | “Erdafitinib (ERDA) monotherapy” NCT06511648 ↗ |
| Known as | JNJ-42756493 | “This phase 1, open-label, multicenter, single-arm, dose-escalation study aimed to evaluate safety, pharmacokinetics (PK), and pharmacodynamics of erdafitinib (JNJ-42756493), an...” PMID 28965185 ↗ Sep 20177“Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.” PMID 31088831 ↗ May 2019 |
| Known as | TAR-210 | “A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants...” NCT06319820 ↗ |
| Action | Inhibit | “pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor” NCT01962532 ↗ |
| Modality | Small molecule | “evaluating the small-molecule FGFR1-4 inhibitor, erdafitinib” PMID 36639200 ↗ May 2023 |
| Route | Oral | “JNJ-42756493 administered orally once daily” NCT01962532 ↗ |
| Target | FGFR1 | “tyrosine kinase inhibitor of FGFR1-4” PMID 31340094 ↗ Jul 2019 |